emodin has been researched along with Alloxan Diabetes in 17 studies
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.
emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with emodin significantly turns down the accelerated cell cycle and proliferation of MCs cultured in high glucose (HG) via inhibiting cFLIP." | 5.40 | Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. ( Cao, S; Gao, J; Guo, C; Su, Z; Wang, F; Wang, W, 2014) |
| "Emodin was divided into high, medium and low dose groups." | 1.91 | Effects of Emodin on Protein Expression Related to Autophagy of Interstitial Cells of Cajal in Diabetic Rats. ( Dong, N; Li, H; Qin, G; Su, Y; Wang, Y; Zhang, M; Zhao, Q; Zhou, Y, 2023) |
| "Treatment of Emodin in DKD models could significantly attenuated these changes and reduced renal injury." | 1.91 | Emodin attenuates diabetic kidney disease by inhibiting ferroptosis via upregulating Nrf2 expression. ( Cao, M; Cui, M; Ji, J; Tao, P; Wang, Q; Xu, Y, 2023) |
| "Treatment of emodin significantly increased the proportion of M2-polarized macrophages and the expression level of TGF-β, a typical ECM formation-related cytokine secreted by the M2 macrophages in the co-cultured supernatant." | 1.72 | Emodin accelerates diabetic wound healing by promoting anti-inflammatory macrophage polarization. ( Chen, C; Guan, S; Hu, Q; Hu, T; Jin, X; Lin, Z; Liu, W; Quan, S; Shen, J; Wang, J; Wu, X; Zhuang, X, 2022) |
| "Alloxan treatment increased the levels of FBG, total cholesterol, LDL-cholesterol, VLDL-cholesterol, urine ketone and cardiac function indices and reduced the levels of globulin, albumin, HDL-cholesterol, globulin, liver glycogen, hexokinase and glucose-6-phosphate dehydrogenase activities." | 1.56 | Identification and characterization of anti-diabetic principle in Senna alata (Linn.) flower using alloxan-induced diabetic male Wistar rats. ( Ajiboye, TO; Ashafa, AOT; Uwazie, JN; Yakubu, MT, 2020) |
| " Nanoparticle encapsulation of drugs is beneficial for drug targeting and bioavailability as well as for lowering drug toxicity side effects." | 1.46 | Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia. ( Gao, Y; Gong, Y; Guo, L; Han, X; Jia, T; Li, G; Li, L; Liang, S; Liu, H; Liu, S; Sheng, X; Shi, L; Wu, B; Xu, H; Yi, Z; Yuan, H; Zhang, C; Zhao, S; Zou, L, 2017) |
| "Emodin did not increase the p-PKB (Ser473) to PKB ratio when the rapamycin-insensitive companion of mTOR was depleted, further supporting the involvement of mammalian target of rapamycin complex 2 in PKB phosphorylation." | 1.42 | 11β-HSD1 modulates LPS-induced innate immune responses in adipocytes by altering expression of PTEN. ( Brown, J; Chu, K; Deng, J; Hong, G; Lai, W; Tian, X; Wei, Y; Xiang, Q; Zhang, S, 2015) |
| "Treatment with emodin significantly turns down the accelerated cell cycle and proliferation of MCs cultured in high glucose (HG) via inhibiting cFLIP." | 1.40 | Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. ( Cao, S; Gao, J; Guo, C; Su, Z; Wang, F; Wang, W, 2014) |
| "Emodin (Emo) has been reported to exhibit protective effects against diabetic nephropathy." | 1.40 | Emodin protects against diabetic cardiomyopathy by regulating the AKT/GSK-3β signaling pathway in the rat model. ( Chen, Q; Deng, W; Ke, D; Li, G; Wu, Z, 2014) |
| "Emodin was efficient to ameliorate renal dysfunction in diabetic nephropathy rats probably by its inhibition of the activation of p38 MAPK pathway and downregulation of the expression of fibronectin." | 1.33 | Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. ( Chen, F; Guo, F; Huang, H; Huang, W; Liu, P; Liu, W; Qin, J; Tang, F; Wang, J; Yang, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, KC | 1 |
| Li, L | 2 |
| Sanborn, TM | 1 |
| Shieh, B | 1 |
| Lenhart, P | 1 |
| Ammar, D | 1 |
| LaBarbera, DV | 1 |
| Petrash, JM | 1 |
| Xu, Y | 2 |
| Li, H | 7 |
| Chen, G | 1 |
| Zhu, L | 1 |
| Lin, H | 1 |
| Huang, C | 1 |
| Wei, S | 1 |
| Yang, T | 1 |
| Qian, W | 1 |
| Li, X | 1 |
| Zhao, S | 2 |
| Pan, W | 1 |
| Chen, C | 1 |
| Lin, Z | 1 |
| Liu, W | 2 |
| Hu, Q | 1 |
| Wang, J | 2 |
| Zhuang, X | 1 |
| Guan, S | 1 |
| Wu, X | 1 |
| Hu, T | 1 |
| Quan, S | 1 |
| Jin, X | 1 |
| Shen, J | 1 |
| Wang, Y | 3 |
| Dong, N | 3 |
| Zhou, Y | 3 |
| Qin, G | 3 |
| Zhao, Q | 3 |
| Zhang, M | 3 |
| Su, Y | 3 |
| Ji, J | 1 |
| Tao, P | 1 |
| Wang, Q | 1 |
| Cui, M | 1 |
| Cao, M | 1 |
| Uwazie, JN | 1 |
| Yakubu, MT | 1 |
| Ashafa, AOT | 1 |
| Ajiboye, TO | 1 |
| Sheng, X | 1 |
| Zou, L | 1 |
| Han, X | 1 |
| Gong, Y | 1 |
| Yuan, H | 1 |
| Shi, L | 1 |
| Guo, L | 1 |
| Jia, T | 1 |
| Liu, S | 1 |
| Wu, B | 1 |
| Yi, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Li, G | 3 |
| Zhang, C | 1 |
| Xu, H | 1 |
| Liang, S | 1 |
| Gao, J | 1 |
| Wang, F | 1 |
| Wang, W | 1 |
| Su, Z | 1 |
| Guo, C | 1 |
| Cao, S | 1 |
| Wu, Z | 1 |
| Chen, Q | 1 |
| Ke, D | 1 |
| Deng, W | 1 |
| Lai, W | 1 |
| Tian, X | 1 |
| Xiang, Q | 1 |
| Chu, K | 1 |
| Wei, Y | 1 |
| Deng, J | 1 |
| Zhang, S | 1 |
| Brown, J | 1 |
| Hong, G | 1 |
| Chen, T | 1 |
| Zheng, LY | 1 |
| Xiao, W | 1 |
| Gui, D | 1 |
| Wang, X | 1 |
| Wang, N | 1 |
| Sohn, E | 1 |
| Kim, J | 1 |
| Kim, CS | 1 |
| Jo, K | 1 |
| Kim, JS | 1 |
| Zhao, XY | 1 |
| Qiao, GF | 1 |
| Li, BX | 1 |
| Chai, LM | 1 |
| Li, Z | 1 |
| Lu, YJ | 1 |
| Yang, BF | 1 |
| Xue, J | 1 |
| Ding, W | 1 |
| Liu, Y | 1 |
| Wang, YJ | 1 |
| Huang, SL | 1 |
| Feng, Y | 1 |
| Ning, MM | 1 |
| Leng, Y | 1 |
| Beppu, H | 1 |
| Shimpo, K | 1 |
| Chihara, T | 1 |
| Kaneko, T | 1 |
| Tamai, I | 1 |
| Yamaji, S | 1 |
| Ozaki, S | 1 |
| Kuzuya, H | 1 |
| Sonoda, S | 1 |
| Huang, H | 1 |
| Liu, P | 1 |
| Tang, F | 1 |
| Qin, J | 1 |
| Huang, W | 1 |
| Chen, F | 1 |
| Guo, F | 1 |
| Yang, B | 1 |
17 other studies available for emodin and Alloxan Diabetes
| Article | Year |
|---|---|
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Animals; Cataract; Diabetes Complications; Diabetes Mellit | 2016 |
Radix polygoni multiflori protects against hippocampal neuronal apoptosis in diabetic encephalopathy by inhibiting the HDAC4/JNK pathway.
Topics: Animals; Apoptosis; Brain Diseases; Diabetes Mellitus, Experimental; Emodin; Hippocampus; Histone De | 2022 |
Emodin accelerates diabetic wound healing by promoting anti-inflammatory macrophage polarization.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Emodin; Macrophages; Mice; NF-ka | 2022 |
Effects of Emodin on Protein Expression Related to Autophagy of Interstitial Cells of Cajal in Diabetic Rats.
Topics: Animals; Autophagy; Beclin-1; Diabetes Mellitus, Experimental; Emodin; Interstitial Cells of Cajal; | 2023 |
Effects of Emodin on Protein Expression Related to Autophagy of Interstitial Cells of Cajal in Diabetic Rats.
Topics: Animals; Autophagy; Beclin-1; Diabetes Mellitus, Experimental; Emodin; Interstitial Cells of Cajal; | 2023 |
Effects of Emodin on Protein Expression Related to Autophagy of Interstitial Cells of Cajal in Diabetic Rats.
Topics: Animals; Autophagy; Beclin-1; Diabetes Mellitus, Experimental; Emodin; Interstitial Cells of Cajal; | 2023 |
Effects of Emodin on Protein Expression Related to Autophagy of Interstitial Cells of Cajal in Diabetic Rats.
Topics: Animals; Autophagy; Beclin-1; Diabetes Mellitus, Experimental; Emodin; Interstitial Cells of Cajal; | 2023 |
Emodin attenuates diabetic kidney disease by inhibiting ferroptosis via upregulating Nrf2 expression.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Emodin; Ferroptosis; | 2023 |
Identification and characterization of anti-diabetic principle in Senna alata (Linn.) flower using alloxan-induced diabetic male Wistar rats.
Topics: Alloxan; alpha-Amylases; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Emodin | 2020 |
Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Emodin; | 2017 |
Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP.
Topics: Animals; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle Checkpoints; Cell P | 2014 |
Emodin protects against diabetic cardiomyopathy by regulating the AKT/GSK-3β signaling pathway in the rat model.
Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyo | 2014 |
11β-HSD1 modulates LPS-induced innate immune responses in adipocytes by altering expression of PTEN.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipocytes; Animals; Cytokines; Diabetes | 2015 |
Emodin ameliorates high glucose induced-podocyte epithelial-mesenchymal transition in-vitro and in-vivo.
Topics: Albuminuria; Animals; Azo Compounds; Blood Glucose; Desmin; Diabetes Mellitus, Experimental; Emodin; | 2015 |
Extract of Rhizoma Polygonum cuspidatum reduces early renal podocyte injury in streptozotocin‑induced diabetic rats and its active compound emodin inhibits methylglyoxal‑mediated glycation of proteins.
Topics: Animals; Apoptosis; Caspase 3; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Emodin; Fall | 2015 |
Hypoglycaemic and hypolipidaemic effects of emodin and its effect on L-type calcium channels in dyslipidaemic-diabetic rats.
Topics: Animals; Blood Glucose; Calcium Channels, L-Type; Diabetes Mellitus, Experimental; Dyslipidemias; Em | 2009 |
Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice.
Topics: Adipocytes; Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Experimental; Dietary Fats; | 2010 |
Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Ad | 2012 |
Antidiabetic effects of dietary administration of Aloe arborescens Miller components on multiple low-dose streptozotocin-induced diabetes in mice: investigation on hypoglycemic action and systemic absorption dynamics of aloe components.
Topics: Aloe; Animals; Anthracenes; Blood Glucose; Diabetes Mellitus, Experimental; Diet; Emodin; Female; Gl | 2006 |
Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats.
Topics: Actins; Animals; Blood Glucose; Blotting, Western; Body Weight; Cyclic AMP Response Element-Binding | 2006 |